Pfizer’s Exubera Cost-Effectiveness Estimates Not Realistic, U.K.’s NICE Says
Pfizer's cost-effectiveness estimates for Exubera submitted to the U.K.'s National Institute for Health & Clinical Excellence are not in line with clinical realities, a NICE committee said
You may also be interested in...
Pfizer will begin direct-to-consumer advertising for its inhaled insulin therapy Exubera approximately one year after its approval, the company said at a June 10 briefing in Washington, D.C
Pfizer/Sanofi-Aventis' post-marketing training program for administering the inhaled insulin powder Exubera with a novel mechanical inhaler needs greater focus, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said in a Sept. 8 review
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011